Literature DB >> 24189203

A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.

Jianmei Wu1, Richard Wiegand, Patricia LoRusso, Jing Li.   

Abstract

The development and validation of a LC-MS/MS method is often performed using pooled human plasma, which may fail to account for variations in interindividual matrices. Since calibrator standards and quality control samples are routinely prepared in pooled human plasma, variations in the extraction recovery and/or matrix effect between pooled plasma and individual patient plasma can cause erroneous measurements. Using both pooled human plasma as well as individual healthy donor and cancer patient plasma samples, we evaluated the analytical performance of two classes of internal standards (i.e., non-isotope-labeled and isotope-labeled) in the quantitative LC-MS/MS analysis of lapatinib. After exhaustive extraction with organic solvent, the recovery of lapatinib, a highly plasma protein-bound drug, varied up to 2.4-fold (range, 29-70%) in 6 different donors of plasma and varied up to 3.5-fold (range, 16-56%) in the pretreatment plasma samples from 6 cancer patients. No apparent matrix effects were observed for lapatinib in both pooled and individual donor or patient plasma samples. The calibration curve range was 5-5000ng/ml of lapatinib in plasma. Both the non-isotope-labeled (zileuton) and isotope-labeled (lapatinib-d3) internal standard methods showed acceptable specificity, accuracy (within 100±10%), and precision (<11%) in the determination of lapatinib in pooled human plasma. Nevertheless, only the isotope-labeled internal standard could correct for the interindividual variability in the recovery of lapatinib from patient plasma samples. As inter- and intra-patient matrix variability is commonly presented in the clinical setting, this study provides an example underscoring the importance of using a stable isotope-labeled internal standard in quantitative LC-MS/MS analysis for therapeutic drug monitoring or pharmacokinetic evaluation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  High performance liquid chromatography (HPLC); Internal standard; LC–MS/MS; Lapatinib; Mass spectrometry; Recovery

Mesh:

Substances:

Year:  2013        PMID: 24189203      PMCID: PMC3848027          DOI: 10.1016/j.jchromb.2013.10.011

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  18 in total

1.  Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development.

Authors:  Showchien Hsieh; Tom Tobien; Kevin Koch; John Dunn
Journal:  Rapid Commun Mass Spectrom       Date:  2004       Impact factor: 2.419

Review 2.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

3.  Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer.

Authors:  J C Duché; S Urien; N Simon; E Malaurie; I Monnet; J Barré
Journal:  Clin Biochem       Date:  2000-04       Impact factor: 3.281

4.  Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone.

Authors:  Nahed El-Najjar; Raimo A Ketola; Teemu Nissilä; Timo Mauriala; Maxim Antopolsky; Janne Jänis; Hala Gali-Muhtasib; Arto Urtti; Heikki Vuorela
Journal:  J Chem Biol       Date:  2011-01-08

5.  Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity.

Authors:  Naila Ahmed; Darin Dobler; Mark Dean; Paul J Thornalley
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

6.  Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.

Authors:  Richard Wiegand; Jianmei Wu; Xianyi Sha; Patricia LoRusso; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-11-27       Impact factor: 3.205

7.  Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Authors:  Sridhar K Rabindran; Carolyn M Discafani; Edward C Rosfjord; Michelle Baxter; M Brawner Floyd; Jonathan Golas; William A Hallett; Bernard D Johnson; Ramaswamy Nilakantan; Elsebe Overbeek; Marvin F Reich; Ru Shen; Xiaoqing Shi; Hwei-Ru Tsou; Yu-Fen Wang; Allan Wissner
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Authors:  N A G Lankheet; M J X Hillebrand; H Rosing; J H M Schellens; J H Beijnen; A D R Huitema
Journal:  Biomed Chromatogr       Date:  2012-09-17       Impact factor: 1.902

9.  Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.

Authors:  Sandra Roche; Gillian McMahon; Martin Clynes; Robert O'Connor
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-10-12       Impact factor: 3.205

10.  Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma.

Authors:  Richard Wiegand; Jianmei Wu; Xianyi Sha; Patricia LoRusso; Elisabeth Heath; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-18       Impact factor: 3.205

View more
  4 in total

1.  Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry.

Authors:  Jianmei Wu; Yingtao Zhang; Richard Wiegand; Jian Wang; Gerold Bepler; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-10-31       Impact factor: 3.205

2.  A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.

Authors:  Xun Bao; Jianmei Wu; Nader Sanai; Jing Li
Journal:  J Pharm Anal       Date:  2017-07-14

3.  Development and Validation of a LC-MS/MS Technique for the Analysis of Short Chain Fatty Acids in Tissues and Biological Fluids without Derivatisation Using Isotope Labelled Internal Standards.

Authors:  Shikha Saha; Priscilla Day-Walsh; Emad Shehata; Paul Anthony Kroon
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

4.  Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry.

Authors:  Xun Bao; Jianmei Wu; Brian Shuch; Patricia LoRusso; Ranjit S Bindra; Jing Li
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.